SignalHF vs Viz HCM

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by Implicity
VS
by Viz.ai

AI Verdict

SignalHF is an AI algorithm focused on predicting heart failure hospitalizations within 30 days by analyzing data from cardiac implantable electronic devices, enabling early intervention for existing heart failure patients. In contrast, Viz HCM is an AI tool designed for the real-time detection of suspected Hypertrophic Cardiomyopathy (HCM) through ECG analysis, aiming to reduce diagnosis time and coordinate care for a specific, often undiagnosed, condition. While both are FDA-cleared AI solutions in cardiology, their distinct applications in disease management versus disease detection make them adjacent rather than direct competitors.

Choose SignalHF if…

Choose SignalHF if your primary objective is to proactively prevent heart failure hospitalizations in patients already equipped with various cardiac implantable electronic devices (CIEDs). This tool is ideal for care teams seeking to leverage manufacturer-agnostic AI analysis of CIED data to identify high-risk patients and enable early, personalized interventions to improve outcomes.

View SignalHF →

Choose Viz HCM if…

Choose Viz HCM if your institution aims to significantly accelerate the detection and streamline the care pathway for patients with suspected Hypertrophic Cardiomyopathy (HCM). This solution is best suited for environments needing real-time AI analysis of ECGs to rapidly identify HCM and efficiently coordinate multidisciplinary care teams, reducing time to diagnosis and treatment.

View Viz HCM →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature SignalHF Viz HCM
Pricing Contact for pricing Subscription-based
Deployment SaaS Cloud-based platform, integrated into hospital IT systems (EHR, PACS).
BAA Available Unknown Yes AI-estimated
FDA Status 1 AI-estimated Yes AI-estimated
HIPAA Unknown Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Viz HCM

Viz HCM emphasizes mobile-based alerts and seamless integration with existing EHR and PACS systems, offering a comprehensive patient view and real-time access to echo images and reports via a mobile app. This focus on immediate, integrated, and mobile access for multidisciplinary teams suggests a highly actionable and user-friendly experience within clinical workflows.

Clinical Value

Viz HCM

While both are FDA-cleared and offer significant clinical benefits, Viz HCM has a more extensive and publicly documented body of clinical validation, including multiple real-world studies and publications demonstrating its effectiveness in detecting HCM and reducing diagnosis time. SignalHF also has clinical validation through the FORESEE-HF study, but Viz HCM's breadth of evidence appears greater.

Pricing & Value

Viz HCM

Viz HCM offers greater transparency regarding its pricing model, explicitly stating it is subscription-based and providing details on CMS reimbursement with specific CPT codes and payment rates effective January 1, 2025. This level of detail allows healthcare systems to better assess the financial value and potential return on investment, whereas SignalHF only states 'Contact for pricing'.

Enterprise Readiness

Viz HCM

Both tools are FDA-cleared, HIPAA compliant, and offer BAAs, indicating a strong foundation for enterprise use. However, Viz HCM explicitly details its extensive integration capabilities with EHR and PACS systems, and its 'Viz.ai One' platform is designed for enterprise-wide care coordination across various specialties, with adoption in over 1,700 hospitals. SignalHF also mentions EHR integration, but Viz HCM's documented integration ecosystem appears more robust and widely implemented.

Innovation

Tie

Both tools demonstrate significant innovation in cardiac care. SignalHF offers manufacturer-agnostic predictive AI for heart failure hospitalizations using data from various CIEDs, including pacemakers, which is a notable advancement. Viz HCM's real-time AI-powered ECG analysis for HCM detection received De Novo FDA approval, establishing a new regulatory category for cardiovascular machine learning-based notification software, highlighting its pioneering nature.

Support & Docs

Viz HCM

Viz HCM provides more explicit and comprehensive details about its support infrastructure, including a dedicated 'Support Center,' 'Help Center,' 'Customer Resources,' 'User Guides,' and 'Viz Academy.' They also offer 24/7/365 urgent phone support and email support. While SignalHF mentions a 'Customer Success team' and responsive support, Viz HCM's documented offerings appear more extensive and readily available.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature SignalHF Viz HCM
Primary Function Predicts heart failure hospitalizations within 30 days. Detects suspected Hypertrophic Cardiomyopathy (HCM) using real-time ECG analysis.
Target Condition Heart Failure Hypertrophic Cardiomyopathy (HCM)
Data Analyzed Data from various cardiac implantable electronic devices (CIEDs), physiological data, demographics, lead measurements, episodes, and therapies. Real-time ECG analysis.
Alert Mechanism Generates automatic alerts for care teams based on risk scores; AI-driven alert management to filter and highlight relevant events. Mobile-based alerts and notifications to multidisciplinary care teams.
Compatibility/Integration Manufacturer-agnostic compatibility with various CIEDs (pacemakers, ICDs, CRTs); Unified platform for centralizing cardiac implantable device data. Seamless integration with existing clinical workflows, EHR, and PACS systems.

Videos

Demos, reviews, and walkthroughs featuring SignalHF and Viz HCM.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

SignalHF by Implicity is designed to predict heart failure hospitalizations within 30 days. In contrast, Viz HCM by Viz.ai focuses on detecting suspected Hypertrophic Cardiomyopathy (HCM) using real-time ECG analysis.
SignalHF analyzes data from various cardiac implantable electronic devices (CIEDs), including pacemakers, ICDs, and CRTs, incorporating physiological data, demographics, lead measurements, episodes, and therapies. Viz HCM, on the other hand, utilizes real-time 12-lead ECG analysis to identify signs associated with HCM.
SignalHF generates automatic alerts for care teams based on risk scores, enabling early intervention and personalized care plans to potentially prevent hospitalizations. Viz HCM provides mobile-based alerts and notifications to multidisciplinary care teams, automating the direction of patients to appropriate care specialists to reduce time to diagnosis and treatment for HCM.
SignalHF offers a unified platform for centralizing cardiac implantable device data and AI-driven alert management. Viz HCM is a cloud-based platform designed for seamless integration with existing clinical workflows, EHR, and PACS systems.
Pricing for SignalHF is not specified, and interested parties need to contact Implicity for details. Viz HCM is subscription-based for hospitals and health systems, with CMS reimbursement available for CPT codes 0764T and 0765T at a national payment rate of $128.90, effective January 1, 2025.
SignalHF's primary benefit is revolutionizing heart failure care with predictive AI, allowing for early intervention by predicting hospitalizations within 30 days. Viz HCM's key benefit is AI-powered disease detection and intelligent care coordination for Hypertrophic Cardiomyopathy, significantly reducing diagnosis time.

Backers

Who funded each tool's parent company.

SignalHF

AI Tool Finder
AI-powered search. Results may not be comprehensive.